Rebiotix is on the forefront of an exciting potential medical breakthrough
Harnessing the Power of the Human Microbiome
Video play time is 1:00 minute.
Rebiotix Inc is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating gastrointestinal (GI) diseases by harnessing the power of the human microbiome.
The company is on the forefront of an exciting potential medical breakthrough with our MRT™ drug platform. The MRT drug platform is for delivering healthy, live, human-derived microbes into a sick patient’s intestinal tract to treat disease.
Rebiotix looks to deliver on the promise of restoring the gut microbiota via a standardized and stabilized drug that has been developed and tested under the auspices of a regulatory authority.
Key Milestones in Harnessing the Power of the Human Microbiome
Rebiotix was founded with $5M
Pre-Investigational New Drug (IND) meeting with FDA for RBX2660
FDA IND granted
Fast Track designation granted
PUNCH CD phase 2 trial enrolled for RBX2660 to treat recurrent Clostridium difficile